Mucins and carbocisteine: respiratory protection


DOI: https://dx.doi.org/10.18565/therapy.2021.10.160-168

Babak S.L., Gorbunova M.V., Malyavin A.G.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Abstract. Increased bronchopulmonary secretion is an important sign of obstructive pulmonary diseases, such as chronic bronchitis, COPD, asthma, bronchiectasis lung disease, which occupy the third place in the world among the leading causes of morbidity and mortality. Tracheobronchial secretions or «normal» mucus play a vital role in protecting the lungs from environmental factors. However, with secretory hyperreactivity with blockage of the small airways, when mucus is the cause of a painful condition, it is called sputum or «pathological» mucus. The universal mechanisms of protection of the bronchopulmonary system largely depend on mucins MUC5AC and MUC5B, which determine the rheological and protective properties of mucus. This review provides a summary of such mechanisms, as well as clinically significant properties of the mucoactive agent carbocisteine, which is a unique mucoregulator with a wide therapeutic window of opportunity in the treatment of chronic pulmonary diseases with mucus hypersecretion.
Keywords: bronchiectasis, MUC5B, MUC5AC, chronic bronchitis, carbocisteine, bronchial asthma, chronic obstructive pulmonary disease
Read entire article

Literature


  1. Janssen W.J., Stefanski A.L., Bochner B.S., Evans C.M. Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions. Eur Respir J. 2016; 48(4): 1201–14. doi: 10.1183/13993003.00120-2015.

  2. Carlier F.M., de Fays C., Pilette C. Epithelial barrier dysfunction in chronic respiratory diseases. Front Physiol. 2021; 12: 691227. doi: 10.3389/fphys.2021.691227.

  3. Li X., Cao X., Guo M. et al. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ. 2020; 368: m234. doi: 10.1136/bmj.m234.

  4. Atanasova K.R., Reznikov L.R. Strategies for measuring airway mucus and mucins. Respir Res. 2019; 20(1): 261. doi: 10.1186/s12931-019-1239-z.

  5. Чучалин А.Г., Абросимов В.Н. Кашель. М: ГЭОТАР-Медиа. 2016; 152 с. [Chuchalin A.G., Abrosimov V.N. Cough. Moscow: GEOTAR-Media. 2016; 152 pp. (In Russ.)]. ISBN: 978-5-9704-3728-5.

  6. Chatterjee M., van Putten J.P.M., Strijbis K. Defensive properties of mucin glycoproteins during respiratory infections-relevance for SARS-CoV-2. mBio. 2020; 11(6): e02374-20. doi: 10.1128/mBio.02374-20.

  7. Hiemstra P.S., McCray P.B. Jr, Bals R. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J. 2015; 45(4): 1150–62. doi: 10.1183/09031936.00141514.

  8. Lillehoj E.P., Kato K., Lu W., Kim K.C. Cellular and molecular biology of airway mucins. Int Rev Cell Mol Biol. 2013; 303: 139–202. doi: 10.1016/B978-0-12-407697-6.00004-0.

  9. Bennett E.P., Mandel U., Clausen H. et al. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012; 22(6): 736–56. doi: 10.1093/glycob/cwr182.

  10. Okuda K., Chen G., Subramani D.B. et al. Localization of secretory mucins MUC5AC and MUC5B in normal/healthy human airways. Am J Respir Crit Care Med. 2019; 199(6): 715–27. doi: 10.1164/rccm.201804-0734OC.

  11. Denneny E., Sahota J., Beatson R. et al. Mucins and their receptors in chronic lung disease. Clin Transl Immunology. 2020; 9(3): e01120. doi: 10.1002/cti2.1120.

  12. Hattrup C.L., Gendler S.J. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008; 70: 431–57. doi: 10.1146/annurev.physiol.70.113006.100659.

  13. Yang D., Xing Y., Song X., Qian Y. The impact of lung microbiota dysbiosis on inflammation. Immunology. 2020; 159(2): 156–66. doi: 10.1111/imm.13139.

  14. Balsamo R., Lanata L., Egan C.G. Mucoactive drugs. Eur Respir Rev. 2010; 19(116): 127–33. doi: 10.1183/09059180.00003510.

  15. Papi A., Avdeev S., Calverley P.M.A. et al. Use of mucolytics in COPD: A Delphi consensus study. Respir Med. 2020; 175: 106190. doi: 10.1016/j.rmed.2020.106190.

  16. Hooper C., Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008; 3(4): 659–69.

  17. Colombo B., Turconi P., Daffonchio L. et al. Stimulation of Cl-secretion by the mucoactive drug S-carboxymethylcysteine-lysine salt in the isolated rabbit trachea. Eur Respir J. 1994; 7(9): 1622–28. doi: 10.1183/09031936.94.07091622.

  18. Maccio A., Madeddu C., Panzone F., Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother. 2009; 10(4): 693–703. doi: 10.1517/14656560902758343.

  19. Carpagnano G.E., Resta O., Foschino-Barbaro M.P. et al. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur J Pharmacol. 2004; 505(1–3): 169–75. doi: 10.1016/j.ejphar.2004.10.007.

  20. Dicpinigaitis P.V. Review: Effect of drugs on human cough reflex sensitivity to inhaled capsaicin. Cough. 2012; 8(1): 10. doi: 10.1186/1745-9974-8-10.

  21. Suer E., Sayrac S., Sarinay E. et al. Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J Infect Chemother. 2008; 14(4): 333–36. doi: 10.1007/s10156-008-0626-z.

  22. Ndour C.T., Ahmed K., Nakagawa T. et al. Modulating effects of mucoregulating drugs on the attachment of Haemophilus influenzae. Microb Pathog. 2001; 30(3): 121–27. doi: 10.1006/mpat.2000.0417.

  23. Braga P.C., Scaglione F., Scarpazza G. et al. Comparison between penetration of amoxicillin combined with carbocysteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int J Clin Pharmacol Res. 1985; 5(5): 331–40.

  24. Yasuda H., Yamaya M., Sasaki T. et al. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J. 2006; 28(1): 51–58. doi: 10.1183/09031936.06.00058505.

  25. Мизерницкий Ю.Л., Ермакова И.Н. Современные мукоактивные препараты в терапии острых респираторных заболеваний у детей. Педиатрия. Приложение к журналу Consilium Medicum. 2007; 1: 53–56. [Mizernitsky Yu.L., Ermakova I.N. The modern mucoactive drugs in therapy of acute respiratory diseases at children. Pediatriya. Prilozheniye k zhurnalu Consilium Medicum = Pediatrics. Consilium Medicum supplement. 2007; 1: 53–56 (In Russ.)].

  26. Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371(9629): 2013–18. doi: 10.1016/S0140-6736(08)60869-7.

  27. Zeng Z., Yang D., Huang X., Xiao Z. Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2277–83. doi: 10.2147/COPD.S140603.

  28. Minov J., Stoleski S., Petrova T. et al. Effects of a long-term use of carbocysteine on frequency and duration of exacerbations in patients with bronchiectasis. Open Access Maced J Med Sci. 2019; 7(23): 4030–35. doi: 10.3889/oamjms.2019.697.


About the Autors

Sergey L. Babak, MD, professor of the Department of phthisiology and pulmonology of the Faculty of general medicine, A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 107150, Moscow, 39/2 Losinoostrovskaya Str. E-mail: sergbabak@mail.ru. ORCID: 0000-0002-6571-1220. Scopus Author ID: 45560913500
Marina V. Gorbunova, PhD, associate professor of the Department of phthisiology and pulmonology of the Faculty of general medicine, A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 107150, Moscow, 39/2 Losinoostrovskaya Str. E-mail: mgorb@mail.ru. ORCID: 0000-0002-2039-0072
Andrey G. Malyavin, MD, professor, professor of the Department of phthisiology and pulmonology of the Faculty of general medicine, A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 107150, Moscow, 39/2 Losinoostrovskaya Str. E-mail: maliavin@mail.ru. Scopus Author ID: 6701876872. ORCID: 0000-0002-6128-5914


Similar Articles

Back to Content

Бионика Медиа